ClinConnect ClinConnect Logo
Search / Trial NCT05799833

Low QRS Voltages in Young Healthy Individuals and Athletes

Launched by IMPERIAL COLLEGE LONDON · Mar 23, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Low Qrs Voltage Low Qrs Amplitude Sudden Cardiac Death Cardiac Magnetic Resonance Myocardial Fibrosis Premature Ventricular Complexes Dilated Cardiomyopathy Arrythmogenic Right Ventricular Cardiomyopathy Arrhythmogenic Left Ventricular Cardiomyopathy Late Gadolinium Enhancement Implantable Cardioverter Defibrillator Cardiopulmonary Exercise Testing Athletes Genetic Inheritance Non Sustained Ventricular Tachycardia Pre Participation Screening Sports Screening

ClinConnect Summary

This clinical trial is exploring the relationship between low electrical signals seen on heart tests (called ECGs) and the risk of serious heart problems, including sudden cardiac death, especially in young healthy individuals and athletes. Researchers are concerned that these low signals might indicate underlying heart issues that could lead to dangerous heart rhythms. Since some athletes have experienced sudden cardiac events even with normal heart tests, the study aims to better understand these ECG findings using advanced heart imaging and other tests.

To participate in this trial, you must be a healthy young person or athlete aged between 18 and 35 years, without any heart-related symptoms or history of heart disease. Participants will undergo various tests, including heart scans and exercise tests, to help determine the significance of the low ECG signals. It's important to note that individuals with a history of heart problems, certain medical conditions, or those who are pregnant cannot participate. This research may help improve guidelines for managing athletes with these ECG findings in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • No cardiovascular symptoms
  • Body mass index \<30.
  • Exclusion Criteria:
  • Individuals with cardiac symptoms;
  • Past medical history of cardiac disease, previous myocarditis or lung disease;
  • Individuals with pacemakers or defibrillators
  • Family history of SCD \<40 years old or cardiomyopathy
  • Pregnant women
  • Advanced kidney and/or liver disease
  • Known thyroid disease,
  • T-wave inversion or other training unrelated ECG changes
  • Known significant valvular heart disease or intra-cardiac shunt on echocardiography.

About Imperial College London

Imperial College London is a world-renowned research institution based in the United Kingdom, recognized for its commitment to advancing medical science and improving patient care through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, Imperial combines expertise across various fields, including medicine, engineering, and business, to drive breakthroughs in healthcare. The institution’s robust clinical trial programs are designed to evaluate new therapies and interventions, ensuring rigorous scientific standards and ethical practices while aiming to translate research findings into tangible benefits for patients and society.

Locations

London, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Sabiha Gati, MBBS

Principal Investigator

Royal Brompton & Harefield NHS Foundation Trust

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials